Aridis Pharmaceuticals Analyst Ratings
Aridis Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/16/2022 | — | Maxim Group | Downgrades | Buy → Hold | |
| 07/20/2021 | 850% | HC Wainwright & Co. | $11 → $19 | Maintains | Buy |
| 05/15/2020 | 450% | HC Wainwright & Co. | $7 → $11 | Reiterates | → Buy |
| 02/19/2020 | 800% | Roth Capital | → $18 | Initiates Coverage On | → Buy |
| 12/30/2019 | 250% | HC Wainwright & Co. | → $7 | Initiates Coverage On | → Buy |
| 09/10/2018 | 1900% | Northcoast Research | → $40 | Initiates Coverage On | → Outperform |
| 09/10/2018 | 1050% | Laidlaw & Co. | → $23 | Initiates Coverage On | → Buy |
| 09/10/2018 | 1150% | Cantor Fitzgerald | → $25 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變化 | 上一頁/當前額定值 |
|---|---|---|---|---|---|
| 08/16/2022 | — | 馬克西姆集團 | 降級 | 買入 → 持有 | |
| 2021 年 7 月 20 日 | 850% | HC Wainwright & Co. | 11 美元 → 19 美元 | 維護 | 買 |
| 05/15/2020 | 450% | HC Wainwright & Co. | 7 美元 → 11 美元 | 重申 | → 購買 |
| 2020 年 2 月 19 日 | 800% | 羅斯資本 | → 18 美元 | 開啓覆蓋範圍 | → 購買 |
| 2019 年 12 月 30 日 | 250% | HC Wainwright & Co. | → 7 美元 | 開啓覆蓋範圍 | → 購買 |
| 2018 年 10 月 9 日 | 1900% | 北海岸研究 | → 40 美元 | 開啓覆蓋範圍 | → 跑贏大盤 |
| 2018 年 10 月 9 日 | 1050% | Laidlaw & Co. | → 23 美元 | 開啓覆蓋範圍 | → 購買 |
| 2018 年 10 月 9 日 | 1150% | 坎託·菲茨傑拉德 | → 25 美元 | 開啓覆蓋範圍 | → 超重 |
Aridis Pharmaceuticals Questions & Answers
Aridis Pharmicals 問題
The latest price target for Aridis Pharmaceuticals (NASDAQ: ARDS) was reported by Maxim Group on August 16, 2022. The analyst firm set a price target for $0.00 expecting ARDS to fall to within 12 months (a possible -100.00% downside). 1 analyst firms have reported ratings in the last year.
Maxim集團於2022年8月16日公佈了阿里迪斯製藥（納斯達克股票代碼：ARDS）的最新目標股價。該分析公司將目標股價定爲0.00美元，預計ARDS將在12個月內降至-100.00％（下行幅度可能爲-100.00％）。去年有1家分析公司公佈了評級。
The latest analyst rating for Aridis Pharmaceuticals (NASDAQ: ARDS) was provided by Maxim Group, and Aridis Pharmaceuticals downgraded their hold rating.
Aridis Pharmicals（納斯達克股票代碼：ARDS）的最新分析師評級由Maxim集團提供，Aridis Pharmicals下調了持有評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aridis Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aridis Pharmaceuticals was filed on August 16, 2022 so you should expect the next rating to be made available sometime around August 16, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表、與Aridis Pharmicals的高管和客戶交談以及聽取財報電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。Aridis Pharmicals的最後一次評級是在2022年8月16日提交的，因此您應該預計下一個評級將在2023年8月16日左右公佈。
While ratings are subjective and will change, the latest Aridis Pharmaceuticals (ARDS) rating was a downgraded with a price target of $0.00 to $0.00. The current price Aridis Pharmaceuticals (ARDS) is trading at is $2.00, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Aridis Pharmicals（ARDS）評級被下調，目標股價爲0.00美元至0.00美元。Aridis Pharmicals（ARDS）目前的交易價格爲2.00美元，超出了分析師的預期區間。